Archives to Collect Info on Radiation Exposure Worldwide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

SPOKANE, Wash-A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

SPOKANE, Wash—A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

The Radiation Health Effects Archives, located on the campus of Gonzaga University, will continue and expand the collection of the Hanford Health Information Archives, founded last year to collect information about the experiences of people who lived in the region around the Hanford, Washington, nuclear facility between 1944 and 1972. These individuals are sometimes referred to as “Hanford downwinders.”

The Hanford-exposure area includes Eastern Washington, northeastern Oregon, and much of Idaho, plus areas along the Columbia River downstream from Hanford. The facility’s airborne emissions were also carried by the wind into parts of Montana and Canada.

The Archives have processed more than 400 donations with information from more than 1,100 downwinders. People have donated medical records, oral histories, journals, yearbooks, photographs, and other items that help describe their lifestyles and diets, as well as their health, from the mid-1940s to the present.

The data are available online at http://www.foley.gonzaga.edu/hhiahome.html. Comments and questions can be sent via e-mail to hhia@foley.gonzaga.edu.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.